UPDATE : Monday, February 17, 2020
상단여백
Prosecutors seek to arrest 2 Kolon execs for false Invossa data by Jeong Sae-im 2019-10-31 15:34
Regulator to do quality test on botulinum toxin products by Jeong Sae-im 2019-10-31 14:24
Syntekabio passes prior review for Kosdaq listing by Jeong Sae-im 2019-10-31 13:27
71 pharmaceutical CEOs gather to boost new drug development by Jeong Sae-im 2019-10-30 12:40
Prosecution seeks jail term for Samsung execs for destroying evidence by Jeong Sae-im 2019-10-29 13:10
라인
KangStem Biotech changes strategy for atopic dermatitis drug by Jeong Sae-im 2019-10-28 15:34
Bridge Biotherapeutics passes preliminary review for Kosdaq listing by Jeong Sae-im 2019-10-25 15:05
KangStem Biotech fails in phase-3 study on atopic dermatitis drug by Jeong Sae-im 2019-10-25 11:17
Value assessment on anticancer drugs hotly discussed by Jeong Sae-im 2019-10-24 13:46
PharmAbcine sets up US unit to develop anticancer drug by Jeong Sae-im 2019-10-23 15:48
라인
‘Oral drugs as effective as inhalers for elderly with asthma’ by Jeong Sae-im 2019-10-22 15:48
Dong-A ST leaves KPBMA to ‘repent of illegal rebate’ by Jeong Sae-im 2019-10-21 16:42
Drug firms’ Q3 earnings to be fairly good by Jeong Sae-im 2019-10-21 12:27
Medytox exported ₩3.3 billion worth of unqualified BTX by Jeong Sae-im 2019-10-18 16:02
US sales of Remicade drop due to biosimilar’s rise by Jeong Sae-im 2019-10-17 13:32
라인
[Exclusive] Samsung admits it failed to develop Rituxan biosimilar by Jeong Sae-im 2019-10-16 14:16
Kolon Life Science shares surge after TissueGene’s survival by Jeong Sae-im 2019-10-14 18:01
HLB merges with Elevar to own rivoceranib rights by Jeong Sae-im 2019-10-14 14:43
‘Kosdaq firms listed for exceptional tech need special monitoring’ by Jeong Sae-im 2019-10-07 15:51
Samsung execs pass buck to biotech subsidiaries for destroying evidence by Jeong Sae-im 2019-10-04 11:42
여백
여백
여백
Back to Top